Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 0

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-282861 Prospectus Supplement (To prospectus dated October 28, 2024) 6,138,108 shares Class A common stock We are offering 6,138,108 shares of our Class A common stock. Our Class A common stock is traded on the Nasdaq Global Market under the symbol “VERA.” On December 9, 2025, the last reported sale price of our Class A common stock on the Nasdaq Global Market was $44.66 per share. The final public offering price will be determined through negotiation between us and the lead underwriters in the offering and the recent market price used throughout this prospectus supplement may not be indicative of the actual offering price.

|                                                      |     | Per share |       |     | Total |             |
|:-----------------------------------------------------|:----|:----------|------:|:----|:------|------------:|
| Public offering price                                |     | $         | 42.50 |     | $     | 260,869,590 |
| Underwriting discounts and commissions(1)            |     | $         |  2.55 |     | $     |  15,652,175 |
| Proceeds to Vera Therapeutics, Inc., before expenses |     | $         | 39.95 |     | $     | 245,217,415 |

| (1) |     | See “Underwriting” for a description of the compensation payable to the underwriters. |

We have granted the underwriters an option to purchase up to an additional 920,716 shares of Class A common stock from us at the public offering price, less underwriting discounts and commissions, within 30 days from the date of this prospectus supplement. See “Underwriting” for more information. Investing in our Class A common stock involves a high degree of risk. See “ Risk factors” beginning on page S-5of this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares to purchasers on or about December 11, 2025.

| Joint book-running managers |

| J.P. Morgan |     | Goldman Sachs & Co. LLC |     | Evercore ISI |     | Cantor |

|